Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of HematologyManagement and Third-Party Investigators to Conduct Conference Call on December 10, 2007 to Discuss SNS-595 Clinical Trial Results and SNS-032 Non-clinical Data
SOUTH SAN FRANCISCO, Calif., November 29, 2007 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing novel anticancer therapeutics, today announced that it will present data on the company's two lead product candidates, SNS-595 and SNS-032, at the upcoming 49th Annual Meeting of the American Society of Hematology (ASH). This year's conference will be held December 8-11, 2007 at the Georgia World Congress Center in Atlanta, Georgia. On December 10, 2007, Sunesis management will host a conference call for investors to discuss the data being presented.
Jeffrey Lancet, M.D., of the H. Lee Moffitt Cancer Center & Research Institute will present results from Sunesis' Phase 1 clinical trial of SNS-595, a replication-dependent DNA damaging agent, as part of the oral session "Acute Myeloid Leukemias: Therapy, excluding Transplantation-Novel Therapies." The presentation, titled "SNS-595 Demonstrates Clinical Responses in a Phase 1 Study in Acute Leukemia," (Abstract no. 442), will be conducted in Room A411-A412 at 2:15 p.m. Eastern Time on Monday, December 10, 2007.
In addition, the company will present non-clinical data on SNS-032, a cyclin-dependent kinase (CDK) inhibitor, during poster session "CLL: Salvage Therapies and New Agents." The poster, "Mechanism of Action of SNS-032, a Novel Cyclin Dependent Kinase Inhibitor, in Chronic Lymphocytic Leukemia: Comparison with Flavopiridol" (Abstract no. 3112) will be presented in Hall B4 of the Georgia World Congress Center on Monday December 10, 2007 from 10:30 a.m. to 7:00 p.m.
Conference Call Information
Sunesis management will host a conference call to discuss data being presented at the ASH meeting on Monday, December 10, 2007 at 4:00 p.m. Eastern Time/1:00 p.m. Pacific Time. Joining management on the call will be clinical investigators involved in the clinical trial of SNS-595and the non-clinical studies of SNS-032.
Individual and institutional investors can access the call via 877-723-9519 (U.S. and Canada) or 719-325-4841 (international). To access the live audio webcast, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at http://www.sunesis.com. Please log on to Sunesis' website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary.
About Sunesis' Oncology Programs
Sunesis has built a rich portfolio of product candidates in oncology focused on novel pathways and targets, including inhibition of the cell-cycle and survival signaling. SNS-595, a replication-dependent DNA damaging agent, is currently in Phase 1 and Phase 1b clinical trials of patients with acute leukemia and a Phase 2 ovarian cancer clinical trial. SNS-032, Sunesis' CDK inhibitor, is being evaluated in a Phase 1 clinical trial in B-cell malignancies. SNS-314, an Aurora kinase inhibitor, is being studied in a Phase 1 dose-escalating clinical trial in patients with advanced solid tumors. In addition, Sunesis is developing novel small molecule inhibitors of Raf kinase and other oncology kinases in collaboration with Biogen Idec.
About Sunesis Pharmaceuticals
Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.
CONTACT: Investors, Eric Bjerkholt, SVP, Corp. Development & Finance ofSunesis Pharmaceuticals, Inc., +1-650-266-3717; or Media, Karen L. Bergmanor Michelle Corral, both of BCC Partners, +1-650-575-1509, or+1-415-794-8662, for Sunesis
Web site: http://www.sunesis.com/
Ticker Symbol: (NASDAQ-NMS:SNSS)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: November 2007